Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any primary ovarian failure in which the cause of the disease is a mutation in the HFM1 gene.
Features include always present findings: Premature ovarian insufficiency, Elevated circulating luteinizing hormone level, Amenorrhea, and Elevated circulating follicle stimulating hormone level and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Lab test results | 2 | Elevated circulating luteinizing hormone level, Elevated circulating follicle stimulating hormone level |
HFM1 encodes helicase for meiosis 1 (1,435 aa). Required for crossover formation and complete synapsis of homologous chromosomes during meiosis Highest expression in Pituitary (17.6 TPM) and Testis (17.2 TPM).
Premature ovarian failure 9 is associated with mutations in the HFM1 gene on chromosome 1.
HFM1 is classified as a druggable target (Enzyme category) with score 0.0.
Genetic testing for HFM1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for premature ovarian failure 9 has been reported in the published literature.
Phenotype severity distribution: 5 always present features.
No clinical trials have been registered for premature ovarian failure 9.
112 publications have been identified in PubMed for premature ovarian failure 9. Research spans Epidemiology / Natural History (40%), Basic Science / Preclinical (18%), and Review / Meta-Analysis (16%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 45 | 40% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 4:31 PM UTC
Online Mendelian Inheritance in Man
Hormones |
1 |
Amenorrhea |
Laboratory research
20 |
18% |
Research summaries | 18 | 16% |
Clinical study results | 12 | 11% |
Patient case studies | 8 | 7% |
New treatment approaches | 4 | 4% |
Other research | 3 | 3% |
Testing and diagnosis research | 2 | 2% |
Grandi G (2026). [PMID: 42132994](https://pubmed.ncbi.nlm.nih.gov/42132994/). *Fam Cancer*. [Epidemiology / Natural History]
Mafra A (2026). [PMID: 41572237](https://pubmed.ncbi.nlm.nih.gov/41572237/). *BMC Womens Health*. [Gene Therapy / Novel Therapeutics]
Cheng X (2026). [PMID: 41826617](https://pubmed.ncbi.nlm.nih.gov/41826617/). *Sci Rep*. [Basic Science / Preclinical]
Yuan Z (2026). [PMID: 39929154](https://pubmed.ncbi.nlm.nih.gov/39929154/). *Horm Res Paediatr*. [Review / Meta-Analysis]
Malick SM (2026). [PMID: 41556851](https://pubmed.ncbi.nlm.nih.gov/41556851/). *Menopause*. [Epidemiology / Natural History]
Yongue G (2026). [PMID: 41663067](https://pubmed.ncbi.nlm.nih.gov/41663067/). *BJOG*. [Review / Meta-Analysis]
Bertolazzi M (2026). [PMID: 41759360](https://pubmed.ncbi.nlm.nih.gov/41759360/). *Eur J Surg Oncol*. [Clinical Trial Publication]
Chen F (2026). [PMID: 41101487](https://pubmed.ncbi.nlm.nih.gov/41101487/). *J Affect Disord*. [Diagnostic / Biomarker]
Chen JH (2026). [PMID: 41640848](https://pubmed.ncbi.nlm.nih.gov/41640848/). *Front Public Health*. [Epidemiology / Natural History]
Li LL (2026). [PMID: 41539956](https://pubmed.ncbi.nlm.nih.gov/41539956/). *Zhonghua Er Ke Za Zhi*. [Basic Science / Preclinical]